Expert Exchange 2021: A Practical Guide to Navigating Novelty in Bladder Cancer: Equipping Clinicians in an Era of Rapid Change
CEC Oncology has incorporated our “Expert Exchange” format for educational activities most recently in our 2020 bladder cancer activities. This Expert Exchange-based format is an educational modality which incorporates elements of a traditional Oxford-style debate, provides enhanced audience interactivity, a broader platform for diverse clinical perspectives, and a flexible framework within which to incorporate evolving science and breaking data. Activity attendees will be immersed a lively and dynamic discussion between key thought leaders in the world of bladder cancer. Top-level experts will debate top-line issues across the disease continuum, and in doing so, provide answers to pivotal clinical questions. Attendees will review the preponderance of checkpoint inhibitor data across the bladder cancer treatment calculus, from NMIBC to MIBC to locally advanced/metastatic disease, and will develop the skills needed to design evidence-based treatment plans for patients experiencing disease progression. Further, experts will provide the tools necessary for effectively embracing the recent explosion of novelty in bladder cancer, including multimodal regimens incorporating chemotherapy, checkpoint inhibition, FGFR inhibition, and antibody-drug conjugates. Finally, the expert panel will offer insights for anticipating and managing immune-related adverse events (irAEs).
Supported through an independent educational grant from AstraZeneca.
Presented by Creative Educational Concepts, Inc. in collaboration with the Bladder Cancer Advocacy Network (BCAN)
ASCO Statement: Not an official event of the 2021 Genitourinary Cancers Symposium. Not sponsored, endorsed, or accredited by any of the cosponsoring organizations of the 2021 Genitourinary Cancers Symposium.
This activity is designed to meet the educational needs of urologists, medical oncologists, surgical oncologists, oncology nurses, and pharmacists and other healthcare professionals that care for bladder cancer patients.
At the conclusion of this live internet activity, participants will be able to:
- Review evolving clinical data for immune checkpoint inhibitors across the bladder cancer disease continuum, including new approvals and guideline recommendations in NMIBC, MIBC, and metastatic disease.
- Design evidence-based treatment plans for patients who experience disease progression.
- Examine the emerging utility of treatment sequencing and/or combinatorial regimens incorporating platinum chemotherapy, checkpoint inhibitors, FGFR inhibitors, and novel antibody-drug conjugates.
- Identify immune-related adverse events (irAEs) that may occur in patients with bladder cancer receiving checkpoint inhibition, and implement adaptive irAE mitigation and management strategies.
10 min Welcome and Introductions/Pre-test
60 min Expert Exchange
20 min Conversations with the Experts/Audience Q&A/Post-test
Robert Dreicer, MD, MS, MACP, FASCO (Chair)
Associate Director for Clinical Research
Deputy Director, University of Virginia Cancer Center
Section Head, Medical Oncology
Co-Director, Paul Mellon Urologic Cancer Institute
Professor of Medicine and Urology
University of Virginia School of Medicine
Dr. Dreicer is the Associate Director for Clinical Research and the Deputy Director of the University of Virginia Cancer Center. He serves as Section Head of Medical Oncology and Co-Director of the Paul Mellon Urologic Cancer Institute. He is a Professor of Medicine and Urology at the University of Virginia School of Medicine in Charlottesville, Virginia. Dr. Dreicer previously served as Chair of the Department of Solid Tumor Oncology at the Cleveland Clinic and Deputy Associate Director for Clinical Research for the Case Comprehensive Cancer Center in Cleveland, Ohio. He is Board Certified in Internal Medicine and Medical Oncology. His areas of specialization are the management of genitourinary malignancies, and the design and conduct of clinical trials in urologic oncology.
Dr. Dreicer received his BS Degree at Colorado State University and his MS Degree at the University of Texas Graduate School of Biomedical Sciences in Houston, Texas. He received his Medical Degree from the University of Texas Medical School in Houston, Texas. He completed an Internal Medicine residency at Indiana University in Indianapolis, Indiana, followed by a Medical Oncology fellowship at the University of Wisconsin Carbone Clinical Cancer Center in Madison, Wisconsin. Dr. Dreicer has published widely in genitourinary oncology and served as Principal Investigator in a large number of studies on genitourinary neoplasms. He has served as Co-Chair of the National Cancer Institute Genitourinary Cancers Steering Committee and is a member of the editorial board of The New England Journal of Medicine’s Journal Watch Hematology and Oncology. In October 2016, he was awarded Mastership in the American College of Physicians.
Sam S. Chang MD, MBA
Patricia and Rodes Hart Endowed Chair of Urologic Surgery
Professor of Urology and Oncology
Chief Surgical Officer, Vanderbilt Ingram Cancer Center
Vanderbilt University Medical Center
Sam S. Chang, MD, MBA, Patricia and Rodes Hart Endowed Professor of Urologic Surgery and Oncology, is the Oncology Fellowship Director and Chief Surgical Officer for Vanderbilt Ingram Cancer Center at Vanderbilt University Medical Center in Nashville, Tennessee. Dr. Chang, a graduate of Princeton University and Vanderbilt University Medical School (where he earned a full 4-year Justin Potter Scholarship), completed his uro-oncology fellowship as Chief Fellow at Memorial Sloan-Kettering Cancer Center. He has also recently completed his MBA at Vanderbilt’s Owen School of Business.
Since his return to Nashville, he has focused on urologic oncology and education and has led efforts in integration of evidence-based medicine in clinical pathways, enhanced national guidelines formulation, and improved urologic cancer staging. He has orchestrated the initiation and expansion of multiple cancer-related treatment protocols at Vanderbilt and elsewhere. Dr. Chang has served as the Chairman of the SUO Panel on Hormone Refractory Prostate Cancer, the chair of the American Joint Committee on Cancer GU Staging Task Force, the Facilitator and Vice-Chair of the Renal Malignancy Follow-Up AUA Guidelines Panel, the Chair of the AUA/ASCO/ASTRO/SUO Guidelines on Nonmetastic Invasive Bladder Cancer, and the Chairman of the AUA Prostate Cancer Core Curriculum Committee. He served as the initial national Prostate Cancer Editor for the AUA Core Curriculum. He is a current member of the NCCN Kidney Cancer Panel and is a Senior Editor of the American Board of Urology Examination committee. In addition, he was named an AUA-EAU Academic Exchange Fellow.
While maintaining a busy clinical surgical practice focused on prostate, kidney and bladder cancer, Dr. Chang has authored more than 275 original publications, multiple book chapters and edited several textbooks. For his academic efforts, he received the SUO’s first-ever Distinguished Service Award, a CaPCURE Prostate Cancer Young Investigator Award, and has been named multiple times as a Journal of Urology’s Best Reviewer. Dr. Chang was named as the 2011 recipient of the American Urologic Association Gold Cystoscope Award and completed a term as a nominated Fellow of the Nashville Health Care Council in 2016. He has been elected (2018-2022) as Assistant Secretary of the American Urological Association in charge of International Relations with Europe and the Middle East.
Elizabeth Plimack, MD, MS
Chief, Division of Genitourinary Medical Oncology
Professor, Department of Hematology/Oncology
Director, Genitourinary Clinical Research
Fox Chase Medical Center
Elizabeth R. Plimack is a Professor of Medical Oncology, Chief of the Division of Genitourinary Medical Oncology and Director of Genitourinary Clinical Research at Fox Chase Cancer Center (FCCC). She is an expert on the treatment of genitourinary malignancies with a focus on bladder and kidney cancers. Her research effort is directed towards the discovery of novel therapeutic approaches and predictive biomarkers for patients with bladder and kidney cancers. Dr. Plimack has extensive clinical trial experience with targeted therapy, immunotherapy and novel combination therapies. She serves on the National Comprehensive Cancer Network guidelines panels for Bladder Cancer and Kidney Cancer, the Bladder Cancer Advocacy Network Management and Think Tank Steering Committees, and on the American Joint Committee on Cancer (AJCC) Urinary Tract Expert Panel. She is an elected member of the American Society of Clinical Oncology Board of Directors (2020-2024). Dr. Plimack received her undergraduate degree from Yale University and completed her M.D. degree and residency in Internal Medicine at the New York University School of Medicine. She went on to a Medical Oncology Fellowship at the MD Anderson Cancer Center, and received a Master’s in Patient Based Biologic Research from the University of Texas Graduate School of Biomedical Science.
In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.
Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.
Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
Susan H. Gitzinger, PharmD, MPA–has no relevant financial relationships to disclose in relation to the content of this activity.
Robert Dreicer, MD, MS, MACP, FASCO–has disclosed that he is a consultant for Astellas, Bayer, Eisai, EMD Serono, Exelixis, Merck, Myovant, Novartis, Pfizer, Propella, SeaGen, and Tavanta.
Sam S. Chang MD, MBA–has disclosed that he is a consultant for Astellas, BMS, GLG, Janssen, Pfizer, UroToday, Uroquen, Urovant, and Want.
Elizabeth Plimack, MD, MS–has disclosed that she is a consultant for BMS, Calithera, Genentech, Infinity Pharma, Janssen, MEI, Merck, Pfizer, and Seattle Genetics. She receives grant/research support from Astellas, BMS, Genentech, and Merck.
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CEC designates this live educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Upon completion of a CE Request Form, statements of credit for physicians will be issued within 30 business days.
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Participation